AU2008229385A1 - Biomarkers of sirtuin activity and methods of use thereof - Google Patents

Biomarkers of sirtuin activity and methods of use thereof Download PDF

Info

Publication number
AU2008229385A1
AU2008229385A1 AU2008229385A AU2008229385A AU2008229385A1 AU 2008229385 A1 AU2008229385 A1 AU 2008229385A1 AU 2008229385 A AU2008229385 A AU 2008229385A AU 2008229385 A AU2008229385 A AU 2008229385A AU 2008229385 A1 AU2008229385 A1 AU 2008229385A1
Authority
AU
Australia
Prior art keywords
sirtuin
biomarker
subject
expression level
mcp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008229385A
Other languages
English (en)
Inventor
Olivier Boss
Andre Iffland
Michael Jirousek
Siva Lavu
Jill Milne
Jesse J. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of AU2008229385A1 publication Critical patent/AU2008229385A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
AU2008229385A 2007-03-19 2008-03-19 Biomarkers of sirtuin activity and methods of use thereof Abandoned AU2008229385A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91873507P 2007-03-19 2007-03-19
US60/918,735 2007-03-19
PCT/US2008/003605 WO2008115518A2 (en) 2007-03-19 2008-03-19 Biomarkers of sirtuin activity and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2008229385A1 true AU2008229385A1 (en) 2008-09-25

Family

ID=39708658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008229385A Abandoned AU2008229385A1 (en) 2007-03-19 2008-03-19 Biomarkers of sirtuin activity and methods of use thereof

Country Status (6)

Country Link
US (1) US20100215632A1 (enExample)
EP (1) EP2126109A2 (enExample)
JP (1) JP2010524432A (enExample)
AU (1) AU2008229385A1 (enExample)
CA (1) CA2680823A1 (enExample)
WO (1) WO2008115518A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) * 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP1955077B1 (en) * 2005-12-02 2012-06-13 Sirtris Pharmaceuticals, Inc. Mass spectrometry assays for acetyltransferase/deacetylase activity
US8391970B2 (en) * 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
BRPI0914006A2 (pt) 2008-07-03 2015-10-27 Sirtris Pharmaceuticals Inc benzimidazóis e análogos relacionados como moduladores de sirtuína
MX349176B (es) 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
BRPI0806044A2 (pt) * 2008-10-17 2010-09-14 União Brasileira De Educação E Assistência - Mantenedora Da Pucrs método e kit para determinação de agentes moduladores de sirtuìnas, processo para modulação de sirtuìnas, compostos moduladores de sirtuìnas e composições compreendendo os mesmos
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
US8996116B2 (en) * 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
WO2011028763A2 (en) * 2009-09-01 2011-03-10 Setpoint Medical Corporation Prescription pad for treatment of inflammatory disorders
WO2011059839A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US20130102009A1 (en) * 2010-04-15 2013-04-25 Han Dai Sirtuin activators and activation assays
RU2693462C2 (ru) 2010-05-03 2019-07-03 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
CN102559850B (zh) * 2010-12-16 2014-03-05 益善生物技术股份有限公司 一种apoA5基因突变检测特异性引物和液相芯片
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2013024821A1 (ja) * 2011-08-12 2013-02-21 国立大学法人筑波大学 並列反応用懸濁液、並列反応方法およびスクリーニング方法
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
RU2612630C2 (ru) * 2014-09-17 2017-03-09 Федеральное бюджетное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ЦНИИ Эпидемиологии Роспотребнадзора) Способ определения индивидуального генетического риска развития ишемического инсульта
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US20190367600A1 (en) * 2017-01-27 2019-12-05 A-Clip Institute, Co., Ltd. Prophylactic and/or therapeutic agent of infectious diseases or inflammatory diseases
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
WO2019109044A1 (en) * 2017-12-01 2019-06-06 The Scripps Research Institute Methods and materials for assessing biological age and slowing the progress of excessive biological aging
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
KR102127903B1 (ko) * 2019-01-29 2020-06-29 연세대학교 산학협력단 염증성 호흡기 질환의 진단용 바이오마커
WO2020210786A1 (en) 2019-04-12 2020-10-15 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
CA3213068A1 (en) 2021-03-25 2022-09-29 Ramot At Tel-Aviv University Ltd. Compositions and articles comprising an adnf polypeptide
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders
US12649059B2 (en) 2022-08-05 2026-06-09 The Feinstein Institutes For Medical Research Methods for reducing bleeding in hemophilia by vagus nerve stimulation to prime platelets

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
WO2008060400A2 (en) * 2006-11-15 2008-05-22 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
US20100168084A1 (en) * 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
WO2008115518A3 (en) 2008-12-24
WO2008115518A2 (en) 2008-09-25
US20100215632A1 (en) 2010-08-26
CA2680823A1 (en) 2008-09-25
JP2010524432A (ja) 2010-07-22
EP2126109A2 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
US20100215632A1 (en) Biomarkers of sirtuin activity and methods of use thereof
US12012634B2 (en) Methods for diagnosing, prognosing, and treating parkinson's disease or parkinsonism
US20230220468A1 (en) Methods for detecting a genetic variation in attractin-like 1 (atrnl1) gene in subject with parkinson's disease
Yamada et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels
Canterini et al. Shortened primary cilium length and dysregulated Sonic hedgehog signaling in Niemann-Pick C1 disease
US20110218229A1 (en) SIRT1 Modulation of Adipogenesis and Adipose Function
WO2002057496A2 (en) Gene expression profiling of endothelium in alzheimer's disease
CA2838516C (en) Als diagnostic method
CN101356286A (zh) 心血管病症的诊断和疗法
Frederiksen et al. Transcriptional profiling of myotubes from patients with type 2 diabetes: no evidence for a primary defect in oxidative phosphorylation genes
JP7120663B2 (ja) 糖尿病性腎臓病の診断することを補助する方法、糖尿病性腎臓病の検査用キット、動物治療方法、及び糖尿病性腎臓病用医薬
US10286042B2 (en) Methods for the treatment of neurological disorders and diseases using FNDC5
Lin et al. A mitochondrial myopathy-associated tRNASer (UCN) 7453G> A mutation alters tRNA metabolism and mitochondrial function
Santoro et al. Resveratrol corrects aberrant splicing of RYR1 pre-mRNA and Ca2+ signal in myotonic dystrophy type 1 myotubes
US8257929B2 (en) Gene expression profiling of Parkinson's Disease
JP2003504007A (ja) 神経変性性疾患における脳の特異的な領域での異なる遺伝子発現
Song et al. Genetics of the metabolic syndrome
Wang et al. S100B gene polymorphisms are associated with the S100B level and Alzheimer’s disease risk by altering the miRNA binding capacity
Morris et al. NPY mRNA expression in the prefrontal cortex: Selective reduction in the superficial white matter of subjects with schizoaffective disorder
Chen et al. PPP2R2B CAG repeat length in the Han Chinese in Taiwan: Association analyses in neurological and psychiatric disorders and potential functional implications
US20060121465A1 (en) Sgk and nedd used as diagnostic and therapeutic targets
US20040248286A1 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
WO2006021807A2 (en) Methods of diagnosis of attention deficit hyperactivity disorder (adhd)
WO2009001095A2 (en) Novel schizophrenia associated genes
US20050118663A1 (en) Methods and compositions for modulating cell proliferation

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application